Featured Research

from universities, journals, and other organizations

Novel therapy improves immune function in teen with rare disease

Date:
April 15, 2011
Source:
Children's Hospital of Philadelphia
Summary:
In a novel approach that works around the gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers used an alternative cell signaling pathway to significantly improve immune function in a 13-year-old boy with the disease. The study provides a proof-of-principle that immunotherapy, which harnesses elements of the body's immune system, may be used to treat this rare but often deadly disorder.

In a novel approach that works around the gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers used an alternative cell signaling pathway to significantly improve immune function in a 13-year-old boy with the disease. The study, at The Children's Hospital of Philadelphia, provides a proof-of-principle that immunotherapy, which harnesses elements of the body's immune system, may be used to treat this rare but often deadly disorder.

Related Articles


"If this encouraging initial result holds up in further clinical studies, we may have a new treatment option for patients with Wiskott-Aldrich syndrome," said pediatric immunologist Jordan S. Orange, M.D., Ph.D., who holds the newly established Jeffrey Modell Endowed Chair in Pediatric Immunology Research at Children's Hospital.

The immunotherapy study appears in the April 2011 issue of The Journal of Clinical Investigation.

Wiskott-Aldrich syndrome (WAS) is a complex immunodeficiency disorder characterized by recurrent infections, eczema and thrombocytopenia (a low platelet count). Mutations in the WAS gene disable its ability to produce WAS protein (WASp), which crucially affects immune cells -- particularly natural killer (NK) cells, a major component of the innate immune system. Without WASp, immune defenses are compromised, leaving WAS patients at risk for premature death from infection and cancers. This risk exists even for patients mildly affected by WAS.

The only current cure for WAS is stem cell transplantation, a potentially risky procedure presently justified in severe cases. In addition, Orange recently contributed to a small experimental study of gene therapy for WAS led by European researchers, which achieved clinical benefits in two severely affected young boys.

The current study represents a different approach from either stem cell transplantation or gene therapy. Instead of introducing normally functioning immune cells or inserting DNA to correct the defective gene, Orange and colleagues identified and made use of an alternative pathway to restoring immune function.

The researchers used interleukin-2 (IL-2), a cytokine, or cell-signaling protein, a naturally occurring molecule with a key role in the immune system. In a series of cell studies, they revealed mechanisms by which IL-2 signals control actin filaments, cell structures that enable natural killer cells to mount an effective immune response.

"IL-2 enables NK cells to become cytotoxic -- to kill foreign cells," said Orange. "This happens even in the absence of WASp, the protein that is deficient in WAS patients." Researchers in Orange's laboratory found that in cell cultures, IL-2 induced the function of a protein called WAVE2, similar to WASp, but independent of it. The WAVE2 protein acted similarly to WASp, but was accessed through an alternative pathway that enables function in NK cells.

Most importantly, IL-2 achieved clinical laboratory benefits in a teenaged patient in this study. The patient, a 13-year-old boy with mild WAS, had suffered recurrent respiratory tract infections and several of his uncles had died prematurely from blood-cell cancers.

The researchers injected the patient with pharmaceutically produced IL-2 in three treatment courses over 27 weeks. At the end of treatment, the patient's NK cells had cytotoxicity nearly identical to that of a healthy control subject. He tolerated the IL-2 treatment well, with only minor skin reactions at the injection site.

"Although follow-up studies will be necessary to investigate long-range benefits and test IL-2 in additional patients, the initial results are encouraging," said Orange. "If cytokines can provide clinical benefits with low toxicity, this may represent an important advance and opportunity for all patients with Wiskott-Aldrich syndrome."

The National Institutes of Health, the National Center for Research Resources, the Jeffrey Modell Foundation, and the Children's Hospital of Philadelphia Research Institute Foundation supported this study.


Story Source:

The above story is based on materials provided by Children's Hospital of Philadelphia. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jordan S. Orange, Sumita Roy-Ghanta, Emily M. Mace, Saumya Maru, Gregory D. Rak, Keri B. Sanborn, Anders Fasth, Rushani Saltzman, Allison Paisley, Linda Monaco-Shawver, Pinaki P. Banerjee, Rahul Pandey. IL-2 induces a WAVE2-dependent pathway for actin reorganization that enables WASp-independent human NK cell function. Journal of Clinical Investigation, 2011; 121 (4): 1535 DOI: 10.1172/JCI44862

Cite This Page:

Children's Hospital of Philadelphia. "Novel therapy improves immune function in teen with rare disease." ScienceDaily. ScienceDaily, 15 April 2011. <www.sciencedaily.com/releases/2011/04/110414171052.htm>.
Children's Hospital of Philadelphia. (2011, April 15). Novel therapy improves immune function in teen with rare disease. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2011/04/110414171052.htm
Children's Hospital of Philadelphia. "Novel therapy improves immune function in teen with rare disease." ScienceDaily. www.sciencedaily.com/releases/2011/04/110414171052.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) — The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) — Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com
Madagascar Working to Contain Plague Outbreak

Madagascar Working to Contain Plague Outbreak

AFP (Nov. 24, 2014) — Madagascar said Monday it is trying to contain an outbreak of plague -- similar to the Black Death that swept Medieval Europe -- that has killed 40 people and is spreading to the capital Antananarivo. Duration: 00:42 Video provided by AFP
Powered by NewsLook.com
Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) — A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins